Cancer Center Profile
A phase III trial investigating ruxolitinib found the oral drug effective at reducing spleen swelling in patients with myelofibrosis, a rare hematologic cancer. Ruxolitinib is an inhibitor of Janus kinases (JAKs) 1 and 2 and interleukin (IL)-6 signaling. Incyte Corporation and Novartis are collaborating on development of ruxolitinib and have announced plans to apply for regulatory approval in the United States and Europe within the next few months based on data from this and another pivotal phase III trial.
Results 1 - 2 of 2